| Literature DB >> 25924610 |
James E Koltes1, Dinesh Kumar2,3, Ranjit S Kataria4, Vickie Cooper5, James M Reecy6.
Abstract
BACKGROUND: Kinase activity of cGMP-dependent, type II, protein kinase (PRKG2) is required for the proliferative to hypertrophic transition of growth plate chondrocytes during endochondral ossification. Loss of PRKG2 function in rodent and bovine models results in dwarfism. The objective of this study was to identify pathways regulated or impacted by PRKG2 loss of function that may be responsible for disproportionate dwarfism at the molecular level.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25924610 PMCID: PMC4419418 DOI: 10.1186/s13104-015-1136-6
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Summary of Gene Ontology (GO) biological processes over-represented in the PMT70 data (p < 0.01, FWFDR < 0.10)
|
|
|
|
|
|
|---|---|---|---|---|
|
| 82 | 10.26% | 0.0001 | 0.02 |
|
| 127 | 15.89% | 0.0002 | 0.02 |
|
| 357 | 44.68% | 0.0004 | 0.02 |
|
| 153 | 19.15% | 0.0004 | 0.02 |
|
| 56 | 7.01% | 0.0004 | 0.01 |
|
| 400 | 50.06% | 0.0010 | 0.03 |
|
| 399 | 49.94% | 0.0010 | 0.02 |
|
| 28 | 3.50% | 0.0011 | 0.02 |
|
| 132 | 16.52% | 0.0011 | 0.02 |
|
| 107 | 13.39% | 0.0011 | 0.02 |
|
| 32 | 4.01% | 0.0030 | 0.04 |
|
| 32 | 4.01% | 0.0030 | 0.04 |
|
| 9 | 1.13% | 0.0042 | 0.05 |
|
| 53 | 6.63% | 0.0053 | 0.06 |
|
| 43 | 5.38% | 0.0056 | 0.06 |
|
| 56 | 7.01% | 0.0056 | 0.06 |
|
| 65 | 8.14% | 0.0067 | 0.06 |
|
| 24 | 3.00% | 0.0073 | 0.06 |
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
Summary of Panther molecular function categories over-represented in the PMT70 data (p < 0.01, FWFDR < 0.10)
|
|
|
|
|
|
|---|---|---|---|---|
|
| 188 | 23.5 | 6.00E-10 | 1.40E-07 |
|
| 299 | 37.4 | 7.40E-09 | 8.80E-07 |
|
| 113 | 14.1 | 1.50E-08 | 1.20E-06 |
|
| 75 | 9.4 | 1.30E-04 | 6.00E-03 |
|
| 137 | 17.1 | 2.80E-04 | 1.10E-02 |
|
| 98 | 12.3 | 7.50E-03 | 9.00E-02 |
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
Summary of biological processes enriched when all three PMT are combined (p < 0.01, FWFDR < 0.10)
|
|
|
|
|
|
|---|---|---|---|---|
|
| 136 | 8.50% | 1.85E-07 | 7.82E-05 |
|
| 149 | 9.31% | 1.01E-07 | 8.51E-05 |
|
| 154 | 9.62% | 4.53E-07 | 1.28E-04 |
|
| 148 | 9.25% | 6.73E-07 | 1.42E-04 |
|
| 152 | 9.50% | 2.39E-06 | 4.03E-04 |
|
| 207 | 12.94% | 6.89E-06 | 9.69E-04 |
|
| 210 | 13.12% | 3.55E-05 | 4.27E-03 |
|
| 108 | 6.75% | 4.13E-05 | 4.35E-03 |
|
| 64 | 4.00% | 6.11E-05 | 5.71E-03 |
|
| 74 | 4.62% | 7.60E-05 | 6.39E-03 |
|
| 369 | 23.06% | 9.27E-05 | 7.09E-03 |
|
| 64 | 4.00% | 1.12E-04 | 7.85E-03 |
|
| 381 | 23.81% | 1.83E-04 | 0.012 |
|
| 94 | 5.88% | 4.13E-04 | 0.025 |
|
| 33 | 2.06% | 5.76E-04 | 0.030 |
|
| 67 | 4.19% | 5.46E-04 | 0.030 |
|
| 77 | 4.81% | 6.41E-04 | 0.031 |
|
| 40 | 2.50% | 7.12E-04 | 0.033 |
|
| 146 | 9.12% | 8.33E-04 | 0.036 |
|
| 64 | 4.00% | 1.33E-03 | 0.050 |
|
| 57 | 3.56% | 1.22E-03 | 0.050 |
|
| 70 | 4.38% | 1.30E-03 | 0.051 |
|
| 129 | 8.06% | 1.77E-03 | 0.063 |
|
| 34 | 2.12% | 2.95E-03 | 0.095 |
|
| 27 | 1.69% | 3.08E-03 | 0.095 |
|
| 105 | 6.56% | 2.85E-03 | 0.096 |
|
| 102 | 6.38% | 3.37E-03 | 0.097 |
|
| 18 | 1.12% | 3.28E-03 | 0.098 |
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
Summary of all pathways with over-represented gene lists from KEGG (p < 0.05)
|
|
|
|
|
|
|---|---|---|---|---|
|
| 29 | 1.8 | 0.0014 | 0.25 |
|
| 31 | 1.9 | 0.0220 | 0.89 |
|
| 14 | 0.9 | 0.0250 | 0.81 |
|
| 16 | 1 | 0.0260 | 0.73 |
|
| 16 | 1 | 0.0290 | 0.69 |
|
| 26 | 1.6 | 0.0520 | 0.84 |
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
Figure 1Enriched genes in PRKG2-null growth plate in the P53 pathway. The P53 differentially expressed gene pathway as drawn by pathway studio software. A total of 38 target genes were identified, many of which were also identified as over-enriched for their own downstream targets by Pathway Studio. Additional details regarding the associated targets and publications supporting these target predictions are provided in Additional file 3.
Figure 2Validation of DE genes in the P53 pathway. The P53 pathway genes validated as differentially expressed by quantitative real-time PCR (p < 0.05). Transcripts BRCA1, BUB1, CEBPA, and CD58 were found to be differentially expressed using the ddCT method, while VDR was differentially expressed when comparing the natural log (ln) starting transcript copy number between genotypes. Fold changes in gene expression are presented, where the genotype with the lowest expression level was set to one to facilitate visualization of fold change differences.